Skip to main content
. 2018 Oct 26;119(9):1086–1093. doi: 10.1038/s41416-018-0235-2

Fig. 2.

Fig. 2

a Maximum change from baseline in tumor size (sum of target lesions) and progression-free survival (PFS). b Maximum change from baseline in tumor size (sum of target lesions) and PFS in patients treated with MM-302 ≥30 mg/m2 (safety population). c Kaplan-Meier graph of PFS in subgroups split by average MM-302 dose intensity and prior anthracycline status (<7.5 mg/m2/week, ≥7.5 mg/m2/week with and without prior anthracycline)